Advancing Personalized Cancer Care: Regulatory Strategies for Health Canada and FDA Approval of mRNA Vaccines.

Health Canada has recognized mRNA technology’s potential, building on its rapid deployment during the COVID-19 pandemic to explore its role in cancer care (Health Canada, 2023). This adaptability positions mRNA as a cornerstone for innovative treatments, aligning with Canada’s emphasis on advancing biologic therapies to address unmet medical needs. Its transient nature ensures safety by avoiding DNA alteration, a priority under Canadian regulatory frameworks. The FDA has similarly embraced mRNA’s success in infectious diseases, catalyzing its oncology applications with a focus on specificity and reduced long term genetic risks. This article outlines a regulatory strategy for securing approval from Health Canada and the FDA, detailing classification, clinical trials, and agency interactions to balance innovation with safety in precision oncology.